Biosimilar Comparable in Safety, Efficacy to Tysabri in Phase 3 Trial
Efficacy and safety of proposed natalizumab biosimilar PB006 versus Tysabri® in patients with relapsing remitting multiple sclerosis: Primary data from the Phase III Antelope study (P6-4.003)
Use of follow-on disease-modifying treatments for multiple sclerosis: Consensus recommendations
Guidelines for Approval of DMT Biosimilars, Use In Europe Drafted
Biosimilar to Tysabri for Relapsing-Remitting MS Is On Its Way
Eye on Pharma: Natalizumab Injunction; Oral Ustekinumab Development; New Study for Secukinumab Biosimilar
Applications for proposed first-of-a-kind multiple sclerosis biosimilar natalizumab accepted by US FDA and EMA
Sandoz Submits 351(k) Application for Biosimilar Natalizumab to Treat MS
